News

Filter

Current filters:

Santaris Pharma

Santaris Pharma in deal with GlaxoSmithKline to develop RNA-targeted medicines

Santaris Pharma in deal with GlaxoSmithKline to develop RNA-targeted medicines

13-01-2014

Santaris Pharma, a Denmark-based clinical-stage biopharma company, has signed an agreement with UK drug…

GlaxoSmithKlineLicensingPharmaceuticalSantaris Pharma

Santaris inks deal with Roche for RNA-targeted medicines

Santaris inks deal with Roche for RNA-targeted medicines

09-01-2014

Danish privately held clinical-stage biopharmaceutical company Santaris Pharma has signed a worldwide…

LicensingPharmaceuticalResearchRocheSantaris Pharma

Shire and Santaris extend strategic alliance

23-08-2013

Danish privately held clinical-stage biopharmaceutical company Santaris Pharma says that its long term…

BiotechnologyLicensingPharmaceuticalRare diseasesResearchSantaris PharmaShire

Santaris Pharma in multi-million dollar deal with Bristol-Myers for RNA-targeted medicines

17-04-2013

Danish privately held clinical-stage biopharmaceutical company Santaris Pharma says it has entered into…

BiotechnologyBristol-Myers SquibbLicensingPharmaceuticalResearchSantaris Pharma

Santaris prevails in patent battle with Isis Pharma

30-11-2011

Denmark-based RNA-targeted therapies developer Santaris Pharma A/S says that it has won two significant…

BiotechnologyIsis PharmaceuticalsNorth AmericaPatentsSantaris Pharma

Denmark’s Santaris could earn over $600 million in expanded deal with Pfizer

05-01-2011

Global drugs behemoth Pfizer (NYSE: PFE) has expanded its collaboration with Danish firm Santaris Pharma…

LicensingPfizerPharmaceuticalResearchSantaris PharmaWyeth

Santaris and miRagen in strategic alliance to develop microRNA-targeted medicines for cardiovascular disease

24-06-2010

Two developers of RNA-based therapeutics, Denmark-headquartered Santaris Pharma A/S and the USA’s…

Cardio-vascularLicensingmiRagen TherapeuticsPharmaceuticalResearchSantaris Pharma

Back to top